Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticalsinc (AGN.CN)

Algernon Pharmaceuticalsinc (AGN.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 14,014
  • Shares Outstanding, K 155,713
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,538 K
  • 60-Month Beta 0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.52
Trade AGN.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.12
  • Most Recent Earnings -0.02 on 02/28/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.075 +20.00%
on 07/22/21
0.130 -30.77%
on 07/05/21
-0.040 (-30.77%)
since 06/30/21
3-Month
0.075 +20.00%
on 07/22/21
0.190 -52.63%
on 05/03/21
-0.085 (-48.57%)
since 04/30/21
52-Week
0.075 +20.00%
on 07/22/21
0.540 -83.33%
on 12/15/20
-0.235 (-72.31%)
since 07/30/20

Most Recent Stories

More News
Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Get a free ticket to the event here:

ENBI.CN : 0.340 (-4.23%)
ENTBF : 0.2637 (-4.90%)
AGN.CN : 0.090 (unch)
Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, announces that it has reached 70% of its enrollment...

AGN.CN : 0.090 (unch)
AGNPF : 0.0700 (unch)
Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, announces that it will not be advancing Ifenprodil...

AGN.CN : 0.090 (unch)
AGNPF : 0.0700 (unch)
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") is pleased to announce that all of the required permits and licenses for the manufacture of its cGMP...

AGN.CN : 0.090 (unch)
AGNPF : 0.0700 (unch)
Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") announces it has initiated a new clinical research program for pancreatic cancer (PC) and NP-120 (Ifenprodil)....

AGN.CN : 0.090 (unch)
AGNPF : 0.0700 (unch)
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") is pleased to highlight an independent research study from the University of Szeged in Hungary describing...

AGN.CN : 0.090 (unch)
AGNPF : 0.0700 (unch)
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding...

AGN.CN : 0.090 (unch)
AGNPF : 0.0700 (unch)
Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin...

AGNPF : 0.0700 (unch)
AGN.CN : 0.090 (unch)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announce that it has reached 50%...

AGNPF : 0.0700 (unch)
AGN.CN : 0.090 (unch)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, announces that it has filed an end of Phase 2...

AGN.CN : 0.090 (unch)
AGNPF : 0.0700 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.097
2nd Resistance Point 0.093
1st Resistance Point 0.092
Last Price 0.090
1st Support Level 0.087
2nd Support Level 0.083
3rd Support Level 0.082

See More

52-Week High 0.540
Fibonacci 61.8% 0.362
Fibonacci 50% 0.308
Fibonacci 38.2% 0.253
Last Price 0.090
52-Week Low 0.075

See More

Business Summary

Algernon Pharmaceuticals Inc is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough, and COVID-19. The company operates in two reportable segments being the development of repurposed therapeutic drugs in Canada and the facilitation...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar